The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non–muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non–muscle-invasive bladder cancer in the event of a bacillus Calmette-Guérin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org. Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Egner, J. R. (2010) · JAMA · doi:10.1001/jama.2010.1525 · Cited by 5,997
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Self-citationPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Sylvester, R. J., van der Meijden, A. P. M., Oosterlinck, W., Witjes, J. A., Bouffioux, C., Denis, L., Newling, D. W. W., & Kurth, K. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.031 · Cited by 3,013
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F. (2017) · European Urology · doi:10.1016/j.eururo.2016.06.010 · Cited by 2,514
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Self-citationvon der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.757 · Cited by 1,850
Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (1976) · Journal of Urology · doi:10.1016/s0022-5347(17)58737-6 · Cited by 1,791
Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., Grimm, M.-O., Bracarda, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,736
Self-citationIntracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors
Morales, A., Eidinger, D., & Bruce, A. W. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.101 · Cited by 1,533
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh, A., Mellado, B., Varlamov, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817323 · Cited by 1,360
Self-citationBalar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30616-2 · Cited by 1,333
Self-citationSYLVESTER, R. J., van der MEIJDEN, A. P. M., & LAMM, D. L. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64273-5 · Cited by 1,312
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 872
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869
Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9761 · Cited by 840
De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Gil, T., Marreaud, S., Daugaard, G., Skoneczna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3571 · Cited by 778
Bellmunt, J., Théodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., Caty, A., Carles, J., Jagiello-Gruszfeld, A., Karyakin, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5534 · Cited by 766
Sharma, P., Callahan, M. K., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 678
Rosenberg, J. E., O’Donnell, P. H., Balar, A. V., McGregor, B. A., Heath, E. I., Yu, E. Y., Galsky, M. D., Hahn, N. M., Gartner, E. M., Pinelli, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01140 · Cited by 642
Sternberg, C. N., de Mulder, P. H. M., Schornagel, J. H., Théodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, F., Spina, M., van Groeningen, C. J., de Balincourt, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2638 · Cited by 628
Surveillance, Epidemiology, and End Results Program
National Cancer Institute (2020) · Definitions · doi:10.32388/5owtl5 · Cited by 626
BÖHLE, A., JOCHAM, D., & BOCK, P. R. (2003) · Journal of Urology · doi:10.1016/s0022-5347(05)64043-8 · Cited by 616
Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30900-2 · Cited by 590
Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585
PD-1 blockade in tumors with mismatch repair deficiency.
Le, D. T., Uram, J. N., Wang, H., Bartlett, B., Kemberling, H., Eyring, A., Skora, A., Azad, N. S., Laheru, D. A., Donehower, R. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.lba100 · Cited by 565
Sternberg, C. N., de Mulder, P., Schornagel, J. H., Theodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, J. A., Spina, M., van Groeningen, C. J., Duclos, B., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.032 · Cited by 542
Bellmunt, J., von der Maase, H., Mead, G. M., Skoneczna, I., De Santis, M., Daugaard, G., Boehle, A., Chevreau, C., Paz-Ares, L., Laufman, L. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6979 · Cited by 526
SYLVESTER, R. J., van der MEIJDEN, A. P. M., WITJES, J. A., & KURTH, K. (2005) · Journal of Urology · doi:10.1097/01.ju.0000162059.64886.1c · Cited by 385
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
McCaffrey, J. A., Hilton, S., Mazumdar, M., Sadan, S., Kelly, W. K., Scher, H. I., & Bajorin, D. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1853 · Cited by 371
Improved Detection of Urothelial Carcinoma In Situ With Hexaminolevulinate Fluorescence Cystoscopy
SCHMIDBAUER, J., WITJES, F., SCHMELLER, N., DONAT, R., SUSANI, M., MARBERGER, M., & MEMBERS OF THE HEXVIX PCB301/01 STUDY GROUP (2004) · Journal of Urology · doi:10.1097/01.ju.0000100480.70769.0e · Cited by 346
JOCHAM, D., WITJES, F., WAGNER, S., ZEYLEMAKER, B., van MOORSELAAR, J., GRIMM, M.-O., MUSCHTER, R., POPKEN, G., KöNIG, F., KNüCHEL, R., et al. (2005) · Journal of Urology · doi:10.1097/01.ju.0000169257.19841.2a · Cited by 336
Plimack, E. R., Bellmunt, J., Gupta, S., Berger, R., Chow, L. Q. M., Juco, J., Lunceford, J., Saraf, S., Perini, R. F., & O'Donnell, P. H. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30007-4 · Cited by 335
Self-citationFradet, Y., Grossman, H. B., Gomella, L., Lerner, S., Cookson, M., Albala, D., Droller, M. J., & PC B302/01 Study Group (2007) · Journal of Urology · doi:10.1016/j.juro.2007.03.028 · Cited by 312
Bladder Cancer: Diagnosis and Treatment.
DeGeorge, K. C., Holt, H. R., & Hodges, S. C. (2017) · PubMed · Cited by 311
van der Meijden, A. P. M., Sylvester, R. J., Oosterlinck, W., Hoeltl, W., & Bono, A. V. (2003) · European Urology · doi:10.1016/s0302-2838(03)00357-9 · Cited by 305
Stenzl, A., Burger, M., Fradet, Y., Mynderse, L. A., Soloway, M. S., Witjes, J. A., Kriegmair, M., Karl, A., Shen, Y., & Grossman, H. B. (2010) · Journal of Urology · doi:10.1016/j.juro.2010.06.148 · Cited by 304
Grossman, H. B., Gomella, L., Fradet, Y., Morales, A., Presti, J., Ritenour, C., Nseyo, U., Droller, M. J., & PC B302/01 Study Group (2007) · Journal of Urology · doi:10.1016/j.juro.2007.03.034 · Cited by 300
Necchi, A., Joseph, R. W., Loriot, Y., Hoffman-Censits, J., Perez-Gracia, J. L., Petrylak, D. P., Derleth, C. L., Tayama, D., Zhu, Q., Ding, B., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx518 · Cited by 299
Self-citationPembrolizumab for the treatment of non-small cell lung cancer
Lim, S. H., Sun, J.-M., Lee, S.-H., Ahn, J. S., Park, K., & Ahn, M.-J. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1145652 · Cited by 282
Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer
Vaughn, D. J., Broome, C. M., Hussain, M., Gutheil, J. C., & Markowitz, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.937 · Cited by 269
Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer
Kaufman, D., Raghavan, D., Carducci, M., Levine, E. G., Murphy, B., Aisner, J., Kuzel, T., Nicol, S., Oh, W., & Stadler, W. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1921 · Cited by 257
Di̇vri̇k, R. T., Yildirim, Ü., Zorlu, F., & Özen, H. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)01002-5 · Cited by 250
Sharma, P., Siefker-Radtke, A., de Braud, F., Basso, U., Calvo, E., Bono, P., Morse, M. A., Ascierto, P. A., Lopez-Martin, J., Brossart, P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00538 · Cited by 243
Self-citationRink, M., Babjuk, M., Catto, J. W. F., Jichlinski, P., Shariat, S. F., Stenzl, A., Stepp, H., Zaak, D., & Witjes, J. A. (2013) · European Urology · doi:10.1016/j.eururo.2013.07.007 · Cited by 240
Pasin, E., Josephson, D. Y., Mitra, A. P., Côté, R. J., & Stein, J. P. (2008) · Europe PMC (PubMed Central) · Cited by 204
MARTÍNEZ-PIÑEIRO, J. A., MARTÍNEZ-PIÑEIRO, L., SOLSONA, E., RODRÍGUEZ, R. H., FERNÁNDEZ GÓMEZ, J. M., MARTÍN, M. G., MOLINA, J. R., COLLADO, A. G., FLORES, N., ISORNA, S., et al. (2005) · Journal of Urology · doi:10.1097/01.ju.0000173919.28835.aa · Cited by 201
Chou, R., Selph, S., Buckley, D. I., Fu, R., Griffin, J. C., Grusing, S., & Gore, J. L. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.12.090 · Cited by 186
Treatment Paradigm Shift May Improve Survival of Patients With High Risk Superficial Bladder Cancer
Raj, G. V., Herr, H., Serio, A. M., Donat, S. M., Bochner, B. H., Vickers, A. J., & Dalbagni, G. (2007) · Journal of Urology · doi:10.1016/j.juro.2006.11.090 · Cited by 180
Self-citationDe Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Skoneczna, I., Marreaud, S., de Wit, R., & Sylvester, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4924 · Cited by 169
van der Meijden, A., Oosterlinck, W., Brausi, M., Kurth, K.-H., Sylvester, R., deBalincourt, C., & Members of the EORTC-GU Group Superficial Bladder Committee, A. (1999) · European Urology · doi:10.1159/000019859 · Cited by 168
Cancer Susceptibility Mutations in Patients With Urothelial Malignancies
Carlo, M. I., Ravichandran, V., Srinavasan, P., Bandlamudi, C., Kemel, Y. M., Ceyhan‐Birsoy, O., Mukherjee, S., Mandelker, D. L., Chaim, J. L., Knežević, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01395 · Cited by 149
van der Meijden, A. P. M., Brausi, M. A., Zambon, V., Kirkels, W. J., de Balincourt, C., Sylvester, R. J., & MEMBERS OF THE EORTC GENITO-URINARY GROUP (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65966-6 · Cited by 133
Huncharek, M. S., McGarry, R. C., & Kupelnick, B. (2001) · PubMed · Cited by 131
Bosschieter, J., Nieuwenhuijzen, J. A., van Ginkel, T., Vis, A. N., Lissenberg-Witte, B. I., Newling, D. W. W., Beckers, G. M. A., & van Moorselaar, R. J. A. (2017) · European Urology · doi:10.1016/j.eururo.2017.06.038 · Cited by 131
Watchful Waiting Policy in Recurrent Ta G1 Bladder Tumors
Gofrit, O. N., Pode, D., Lazar, A., et al. (2006) · European Urology · doi:10.1016/j.eururo.2005.12.029 · Cited by 119
Papamichael, D., Gallagher, C., Oliver, R. T. D., Johnson, P., & Waxman, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.106 · Cited by 118
Ross, J. S., Wang, K., Khaira, D., Ali, S. M., Fisher, H. A. G., Mian, B. M., Nazeer, T., Elvin, J. A., Palma, N. A., Yelensky, R., et al. (2015) · Cancer · doi:10.1002/cncr.29826 · Cited by 115
Self-citationKamat, A. M., Joaquim Bellmunt, B., Galsky, M. D., Konety, B. R., Lamm, D. L., Langham, D., Lee, C. T., Milowsky, M. I., O’Donnell, M. A., O’Donnell, P. H., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0271-0 · Cited by 99
Klaassen, Z. W. A., Kamat, A. M., Kassouf, W., Gontero, P., Villavicencio, H., Joaquim Bellmunt, B., van Rhijn, B. W. G., Hartmann, A., Catto, J. W. F., & Kulkarni, G. S. (2018) · European Urology · doi:10.1016/j.eururo.2018.06.024 · Cited by 94
Intravesical gemcitabine for non-muscle invasive bladder cancer
Jones, G., Cleves, A., Wilt, T. J., MASON, M. D., Kynaston, H., & Shelley, M. D. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009294.pub2 · Cited by 91
Mari, A., Kimura, S., Foerster, B., Abufaraj, M. M., D’Andrea, D., Hassler, M. R., Minervini, A., Morgan Rouprêt, A., Babjuk, M. M., & Shariat, S. F. (2018) · British Journal of Urology · doi:10.1111/bju.14417 · Cited by 84
Xiong, Y., Li, J., Ma, S., Ge, J., Zhou, L., Li, D., & Chen, Q. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170819 · Cited by 77
Yuan, H., Qiu, J., Liu, L., Zheng, S., Yang, L., Liu, Z., Pu, C., Li, J., Wei, Q., & Han, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074142 · Cited by 50
Patel, V. G., Lorduy, A. C., Stern, A. S., Fahmy, O., Pinotti, R., Galsky, M. D., & Gakis, G. (2017) · Bladder Cancer · doi:10.3233/blc-170108 · Cited by 45
Faltas, B. M., Gennarelli, R. L., Elkin, E. B., Nguyen, D. P., Hu, J. C., & Tagawa, S. T. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.09.009 · Cited by 28
Pal, S. K., Hoffman-Censits, J. H., Zheng, H., Kaiser, C., Tayama, D., & Joaquim Bellmunt, B. (2018) · European Urology · doi:10.1016/j.eururo.2018.02.010 · Cited by 27
Self-citationWelty, C. J., Wright, J. L., Hotaling, J. M., Bhatti, P., Porter, M. P., & White, E. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.09.001 · Cited by 26
Self-citationIntravesical gemcitabine for non-muscle invasive bladder cancer
Jones, G., Cleves, A., Wilt, T. J., MASON, M. D., Kynaston, H., & Shelley, M. D. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009294 · Cited by 10
Cited by
Dyrskjøt, L., Hansel, D. E., Efstathiou, J. A., Knowles, M. A., Galsky, M. D., Teoh, J., & Theodorescu, D. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00468-9 · Cited by 544
Self-citationEndoplasmic Reticulum Stress and Tumor Microenvironment in Bladder Cancer: The Missing Link
Nie, Z., Chen, M., Wen, X., Gao, Y., Huang, D., Cao, H., Peng, Y., Guo, N., Ni, J., & Zhang, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.683940 · Cited by 43
Metadata
- Authors
- Flaig, T. W., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Chang, S., Downs, T. M., Efstathiou, J. A., Friedlander, T., Greenberg, R. E., Guru, K. A., Guzzo, T., Herr, H. W., Hoffman-Censits, J., Hoimes, C., Inman, B. A., Jimbo, M., Kader, A. K., Lele, S. M., Michalski, J., Montgomery, J. S., Nandagopal, L., Pagliaro, L. C., Pal, S. K., Patterson, A., Plimack, E. R., Pohar, K. S., Preston, M. A., Sexton, W. J., Siefker-Radtke, A. O., Tward, J., Wright, J. L., Gurski, L. A., & Johnson-Chilla, A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2020-03
- Volume
- 18
- Issue
- 3
- Pages
- 329-354
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W4242669880
- Cited by
- 626
- References
- 77
- FWCI
- 90.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.